Marketdash
Back to News

Five Stock Upgrades That Caught Wall Street's Attention on Thursday

MarketDash Editorial Team
17 days ago
Wall Street analysts shifted their stance on several notable companies, with Nasdaq getting a particularly strong boost from Morgan Stanley. Here's the full rundown of Thursday's most significant rating upgrades.

Thursday brought a flurry of positive rating changes from top Wall Street analysts, with five companies catching upgrades that moved the needle on sentiment.

The most notable shift came from Morgan Stanley analyst Michael Cyprys, who upgraded Nasdaq Inc (NDAQ) from Equal-Weight to Overweight and raised the price target from $97 to $110. That's a meaningful vote of confidence considering shares closed Wednesday at $86.91, suggesting Cyprys sees roughly 27% upside from current levels.

BTIG analyst Ryan Zimmerman had a change of heart on AVITA Medical Inc (RCEL), upgrading the medical device company from Sell to Neutral. AVITA Medical shares closed at $3.95 on Wednesday, and while Neutral isn't exactly a ringing endorsement, it's a significant improvement from a Sell rating.

Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals Inc (AGIO) from Market Perform to Outperform, though he simultaneously cut the price target from $40 to $34. It's an interesting mix of signals—more bullish on the stock's relative performance, but perhaps less optimistic about the overall sector or near-term catalysts. Agios shares closed at $22.34 on Wednesday, so even the reduced target suggests substantial upside.

Barclays analyst Alex Scott upgraded Marsh & McLennan Companies Inc (MMC) from Equal-Weight to Overweight, though the price target actually declined from $221 to $206. Marsh & McLennan closed at $177.33 on Wednesday, meaning Scott still sees meaningful appreciation potential despite the lowered target.

Rounding out the upgrades, William Blair analyst Louie DiPalma moved Parsons Corp (PSN) from Market Perform to Outperform. Parsons shares closed at $82.64 on Wednesday as the defense and infrastructure contractor earned more bullish analyst attention.

These rating changes reflect evolving analyst perspectives on company fundamentals, market positioning, and growth trajectories. While upgrades don't guarantee future performance, they often signal that analysts see improving risk-reward profiles or catalysts on the horizon.

Back to News

Five Stock Upgrades That Caught Wall Street's Attention on Thursday

MarketDash Editorial Team
17 days ago
Wall Street analysts shifted their stance on several notable companies, with Nasdaq getting a particularly strong boost from Morgan Stanley. Here's the full rundown of Thursday's most significant rating upgrades.

Thursday brought a flurry of positive rating changes from top Wall Street analysts, with five companies catching upgrades that moved the needle on sentiment.

The most notable shift came from Morgan Stanley analyst Michael Cyprys, who upgraded Nasdaq Inc (NDAQ) from Equal-Weight to Overweight and raised the price target from $97 to $110. That's a meaningful vote of confidence considering shares closed Wednesday at $86.91, suggesting Cyprys sees roughly 27% upside from current levels.

BTIG analyst Ryan Zimmerman had a change of heart on AVITA Medical Inc (RCEL), upgrading the medical device company from Sell to Neutral. AVITA Medical shares closed at $3.95 on Wednesday, and while Neutral isn't exactly a ringing endorsement, it's a significant improvement from a Sell rating.

Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals Inc (AGIO) from Market Perform to Outperform, though he simultaneously cut the price target from $40 to $34. It's an interesting mix of signals—more bullish on the stock's relative performance, but perhaps less optimistic about the overall sector or near-term catalysts. Agios shares closed at $22.34 on Wednesday, so even the reduced target suggests substantial upside.

Barclays analyst Alex Scott upgraded Marsh & McLennan Companies Inc (MMC) from Equal-Weight to Overweight, though the price target actually declined from $221 to $206. Marsh & McLennan closed at $177.33 on Wednesday, meaning Scott still sees meaningful appreciation potential despite the lowered target.

Rounding out the upgrades, William Blair analyst Louie DiPalma moved Parsons Corp (PSN) from Market Perform to Outperform. Parsons shares closed at $82.64 on Wednesday as the defense and infrastructure contractor earned more bullish analyst attention.

These rating changes reflect evolving analyst perspectives on company fundamentals, market positioning, and growth trajectories. While upgrades don't guarantee future performance, they often signal that analysts see improving risk-reward profiles or catalysts on the horizon.

    Five Stock Upgrades That Caught Wall Street's Attention on Thursday - MarketDash News